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This lecture considers the pharmacotherapy of depression with EPA under the following headings:
• Epidemiological evidence • Biochemical evidence • First trial of pure EPA in severe treatment-resistant depression
• Subsequent randomized double-blind placebocontrolled trials
• Putative mechanisms. Results obtained from our own group, including structural neuroimaging and 31-phosphorus neurospectroscopy findings, showing an association of EPA treatment of depression with a marked decrease in cerebral phosphodiesters, a marked increase in cerebral phosphomonoesters and reduced lateral ventricular volume, will also be presented. Imperial College London, UK Puri Annals of General Psychiatry 2010, 9(Suppl 1):S23 http://www.annals-general-psychiatry.com/content/9/S1/S23
